VeriSIM Life to acquire Molomics Biotech.

VeriSIM Life, a drug development company, agreed to acquire Molomics Biotech, a privately-held drug discovery company that leverages proprietary AI technology. Financial terms were not disclosed. “This acquisition represents a considerable step forward in our strategy to accelerate our growth over the long term and supplement our proprietary software platform to develop effective patient therapies more rapidly and accurately than traditional methods. Along with advancing research in Parkinson’s Disease, we plan to cover the full spectrum of drug discovery and development for the treatment of neurological, oncological and other life-threatening diseases," Jo Varshney, VeriSIM Life Founder and CEO.